(a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 65% identity with amino acids 20 to 464 of SEQ ID NO:2;

(b) a nucleic acid sequence having at least 65% homology with nucleotides 568 to 2045 of SEQ ID NO:1;

(c) a nucleic acid sequence which hybridizes under low stringency conditions with (i) nucleotides 568 to 2045 of SEQ ID NO:1, (ii) the cDNA sequence contained in nucleotides 568 to 2045 of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);

(d) an allelic variant of (a), (b), or (c); and

(f) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide fragment which has phospholipase B activity.

52. The nucleic acid sequence of claim 51, which encodes a polypeptide having an amino acid sequence which has at least 65% identity with amino acids 20 to 464 of SEQ ID NO:2.

53. The nucleic acid sequence of claim 51, which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

54. The nucleic acid sequence of claim 51, which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or a fragment thereof which has phospholipase B activity.

55. The nucleic acid sequence of claim 54, which encodes a polypeptide consisting of amino acids 20 to 264 of SEQ ID NO:2.

56. The nucleic acid sequence of claim 51, which has at least 65% homology with the nucleic acid sequence of SEQ ID NO:1.

57. The nucleic acid sequence of claim 51, which has the nucleic acid sequence of SEQ ID NO:1.

58. The nucleic acid sequence of claim 51, wherein the nucleic acid sequence hybridizes under low stringency conditions with (i) nucleotides 568 to 2045 of SEQ ID NO:1, (ii) the cDNA sequence contained in nucleotides 568 to 2045 of SEQ ID NO:1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii).

59. The nucleic acid sequence of claim 58, wherein the nucleic acid sequence hybridizes under low stringency conditions with (i) nucleotides 568 to 2045 of SEQ ID NO:1, (ii) the cDNA sequence contained in nucleotides 568 to 2045 of SEQ ID NO:1, or (iii) a complementary strand of (i) or(ii).

60. The nucleic acid sequence of claim 51, which is contained in the plasmid pPH6 which is contained in *E. coli* NRRL B-30142.

61. An isolated nucleic acid sequence produced by (a) hybridizing a DNA under low stringency conditions with (i) nucleotides 568 to 2045 of SEQ ID NO. 1, (ii) the cDNA sequence contained in nucleotides 568 to 2045 of SEQ ID NO. 1, (iii) a subsequence of (i) or (ii) of at least 100 nucleotides, or (iv) a complementary strand of (i), (ii), or (iii); and (b) isolating the nucleic acid sequence.

62. A nucleic acid construct comprising the nucleic acid sequence of claim 51 operably linked to one or more control sequences which direct the production of the polypeptide in a suitable expression host.

63. A recombinant expression vector comprising the nucleic acid construct of claim 62, a promoter, and transcriptional and translational stop signals.

64. A recombinant host cell comprising the nucleic acid construct of claim 62.

65. A method for producing a polypeptide having phospholipase B activity comprising (a) cultivating a strain comprising the nucleic acid sequence of claim 51 under conditions suitable for producing the polypeptide; and (b) recovering the polypeptide.

66. A method for producing a polypeptide having phospholipase B activity comprising (a) cultivating the host cell of claim 65 under conditions suitable for production of the polypeptide; and (b) recovering the polypeptide.

67. A nucleic acid construct comprising a gene encoding a protein operably linked to a nucleic acid sequence encoding a signal peptide consisting of nucleotides 510 to 567 of SEQ ID NO. 1, wherein the gene is foreign to the nucleic acid sequence.

68. A recombinant expression vector comprising the nucleic acid construct of claim 67.

69. A recombinant host cell comprising the nucleic acid construct of claim 67.

70. A method for producing a protein comprising (a) cultivating the recombinant host cell of claim 69 under conditions suitable for production of the protein; and (b) recovering the protein.

REMARKS

This amendment is submitted to add claims. Since there is no new matter added, entry of the amendment is respectfully requested.

Respectfully submitted,

Date: July 13, 2000

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123